Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bertilimumab in moderate to severe ulcerative colitis
NCT01671956Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bertilimumab in ulcerative colitis (UC), sponsored by Alexion Pharmaceuticals. Started Jul 2015; status: terminated.
02
Drugs
bertilimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01671956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01671956.